CorMedix Inc (NYSEMKT:CRMD), A drop of 188,872 shares or 3.6% was seen in the short interest of CorMedix Inc.. Even as the interest dropped from 5,231,007 shares on May 31,2016 to 5,042,135 shares on June 15,2016, the days to cover came in at 20. The updated interest stood at 14.2% of the stocks floats. The stock has seen an average daily volume of 256,871 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
CorMedix Inc (NYSEMKT:CRMD): The stock opened at $1.90 on Friday but the bulls could not build on the opening and the stock topped out at $2.03 for the day. The stock traded down to $1.85 during the day, due to lack of any buying support eventually closed down at $1.91 with a loss of -7.28% for the day. The stock had closed at $2.06 on the previous day. The total traded volume was 3,480,583 shares.
The company shares have dropped -52.84% from its 1 Year high price. On Jun 29, 2015, the shares registered one year high at $4.78 and the one year low was seen on Jan 14, 2016. The 50-Day Moving Average price is $2.61 and the 200 Day Moving Average price is recorded at $2.47.
CorMedix Inc (NYSEMKT:CRMD) has tumbled 11.16% during the past week and has dropped 32.51% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 9.69%. CorMedix Inc (NYSEMKT:CRMD) has underperformed the index by 30.47% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
CorMedix Inc. (CorMedix) is a pharmaceutical company that in-licenses, develops and commercializes prophylactic and therapeutic products for the treatment of infectious diseases in cardiac, renal and oncology patients. The Company has in-licensed all of the products in its pipeline. The Companys primary product is Neutrolin, a catheter lock solution, which is used the treatment of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. It has the worldwide rights to develop and commercialize product candidates, CRMD003 (Neutrolin) and CRMD004. The Company manufactures CRMD003 (Neutrolin) through Navinta LLC, a United States-based active pharmaceutical ingredient (API) developer. The CRMD004 is the gel formulation of Neutrolin, which is in the pre-clinical stage of development.